@article {Wang1262, author = {Jiantao Wang and Anren Kuang}, title = {Analysis of the 131I therapy in the young and adolescent patients with differentiated thyroid carcinoma}, volume = {56}, number = {supplement 3}, pages = {1262--1262}, year = {2015}, publisher = {Society of Nuclear Medicine}, abstract = {1262 Objectives To evaluate the characteristics and the effects of the 131I therapy in the children and adolescents with differentiated thyroid cancer(DTC) .Methods The clinical and follow up data of 38 patients with DTC who received initial 131I treatment at the age<=20 years old(6 to 20 years old)were retrospectively analysed.There were 36 patients with papillary thyroid carcinoma, 1 with follicular thyroid carcinoma and 1 with mixed thyroid carcinoma.21 patients experienced simple lymph node metastases found by the surgery pathology, and 7 had lung metastases as well as lymph metastasis.All patients received 131 ablation of residual thyroid tissues.Therapeutic doses of metastatic loci were adjusted according to age,illness status,location of metastasis and uptake of 131I of lesions.Therapeutic effects were evaluated by the levels of serum thyroglobulin and its receptor,and adverse effects were also observed.Results The median time of follow up was 25.3 months(6 to 50 months),and no patient died during this period.11 patients were complete remission,25 patients were partial remission and 2 progressed.5 patients suffered vomit, and the components of the peripheral in all the patients showed a slight temporal decrease, while still normal. No pulmonary fibrosis,secondary malignancies and abnormity of growth and development were found during follow-up.Conclusions More recurrence and metastasis were found in children and adolescents with DTC, 131I therapy is an effective and safe method for young patients with DTC.Research Support none}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/56/supplement_3/1262}, eprint = {https://jnm.snmjournals.org/content}, journal = {Journal of Nuclear Medicine} }